Search Results - "Bass, Damon L."

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis by Wilkinson, Christel, Henderson, Robert B, Jones-Leone, Angela R, Flint, Shaun M, Lennon, Mark, Levy, Roger A, Ji, Beulah, Bass, Damon L, Roth, David

“…Elevated B lymphocyte stimulator (BLyS) levels in patients with systemic lupus erythematosus (SLE) correlate positively with disease activity; BLyS expression…”
Get full text

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study by Bae, Sang-Cheol, Bass, Damon L, Chu, Myron, Curtis, Paula, Dimelow, Richard, Harvey, Laurence, Ji, Beulah, Kurrasch, Regina, Muzaffar, Saima, Punwaney, Raj, Roth, David A, Song, Yeong-Wook, Xie, Wendy, Zhang, Fengchun

“…Treatment goals for patients with systemic lupus erythematosus (SLE) include minimising disease activity and reducing the risk of flares. Although belimumab is…”
Get full text

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison by Brunner, Hermine I, Abud-Mendoza, Carlos, Mori, Masaaki, Pilkington, Clarissa A, Syed, Reema, Takei, Syuji, Viola, Diego O, Furie, Richard A, Navarra, Sandra, Zhang, Fengchun, Bass, Damon L, Eriksson, Gina, Hammer, Anne E, Ji, Beulah N, Okily, Mohamed, Roth, David A, Quasny, Holly, Ruperto, Nicolino

“…ObjectiveTo assess the efficacy and safety of belimumab in paediatric versus adult patients with systemic lupus erythematosus (SLE).MethodsWe performed…”
Get full text

Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus by Ginzler, Ellen, Guedes Barbosa, Luiz Sergio, D'Cruz, David, Furie, Richard, Maksimowicz‐McKinnon, Kathleen, Oates, James, Santiago, Mittermayer Barreto, Saxena, Amit, Sheikh, Saira, Bass, Damon L., Burriss, Susan W., Gilbride, Jennifer A., Groark, James G., Miller, Michelle, Pierce, Amy, Roth, David A., Ji, Beulah

“…Objective Enrollment of patients of Black African ancestry with systemic lupus erythematosus (SLE) in phase II and phase III of the belimumab trials was not…”
Get full text

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus by Urowitz, Murray B., Aranow, Cynthia, Asukai, Yumi, Bass, Damon L., Bruce, Ian N., Chauhan, Deven, Dall'Era, Maria, Furie, Richard, Fox, Norma Lynn, Gilbride, Jennifer A., Hammer, Anne, Ginzler, Ellen M., Gonzalez‐Rivera, Tania, Levy, Roger A., Merrill, Joan T., Quasny, Holly, Roth, David A., Stohl, William, Vollenhoven, Ronald, Wallace, Daniel J., Petri, Michelle

“…Organ damage is a key determinant of poor long‐term prognosis and early death in patients with systemic lupus erythematosus (SLE). Prevention of damage is a…”
Get full text

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme by Maslen, Toni, Bruce, Ian N, D'Cruz, David, Ianosev, Mihaela, Bass, Damon L, Wilkinson, Christel, Roth, David A

“…ObjectiveTo assess the appropriateness of expanded serological activity eligibility criteria for belimumab use in the UK systemic lupus erythematosus (SLE)…”
Get full text

P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies by Bass, Damon L, Okily, Mohamed, Hammer, Anne, Ji, Beulah, Roth, David, Quasny, Holly

“…BackgroundBelimumab is approved as add-on therapy for patients ≥5 years with active, autoantibody-positive systemic lupus erythematosus (SLE).1 The PLUTO trial…”
Get full text